KR920701472A - 당뇨병 예보자의 정량 분석 - Google Patents

당뇨병 예보자의 정량 분석

Info

Publication number
KR920701472A
KR920701472A KR1019910701268A KR910701268A KR920701472A KR 920701472 A KR920701472 A KR 920701472A KR 1019910701268 A KR1019910701268 A KR 1019910701268A KR 910701268 A KR910701268 A KR 910701268A KR 920701472 A KR920701472 A KR 920701472A
Authority
KR
South Korea
Prior art keywords
inositol
chiro
insulin resistance
patient
concentration
Prior art date
Application number
KR1019910701268A
Other languages
English (en)
Other versions
KR0175314B1 (ko
Inventor
알리손 에스. 케닝톤
조셉 라너
Original Assignee
원본미기재
더 유니버시티 오브 버지니아 페이턴츠 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 유니버시티 오브 버지니아 페이턴츠 파운데이션 filed Critical 원본미기재
Publication of KR920701472A publication Critical patent/KR920701472A/ko
Application granted granted Critical
Publication of KR0175314B1 publication Critical patent/KR0175314B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

내용 없음

Description

당뇨병 예보자의 정량 분석
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 포유 동물 환자로부터 혈청 시료 및 뇨 시료로 이루어진 군중에서 선택되는 시료를 채취하고, 시료의 키로-이노시톨 농도를 측정하여 뇨 키로-이노시톨 농도 약 1.0㎍/ml 미만이면 상기 환자에서 인슐린 저항성이 예견되는 것으로 분석함을 특징으로 하는, 포유 동물 환자의 당뇨병 증상과 관련된 잠재적 인슐린 저항성의 진단 방법.
  2. 제1항에 있어서, 약 0.3㎍/ml 미만의 상기 뇨 시료 중의 키로-이노시콜 농도 및 약 0.03㎍/ml 미만의 혈청시료 중의 키로-이노시톨 농도는 상기 환자에서의 인슐린 저항성을 나타내고, 0.3㎍/ml 내지 약 1㎍/ml의 뇨 시료 중의 키로-이노시톨 농도 및 0.03 내지 0.1㎍/ml의 형청 키로-이노시톨 농도는 인슐린 저항성 예비 증상을 나타냄을 특징으로 하는 방법.
  3. 제1항에 있어서, 상기 분석 단계를 가스 크로카토그래피/질량분광 분석, 종이 크로카토그래피, 키로-이소시톨 효소 특이성 환원/산화 분석, 키로-이노시톨에 특이적인 항체를 이용한 분석, 이들의 조합으로 이루어진 군중에서 선택된 분석법을 사용하여 수행함을 특징으로 하는 방법.
  4. 제3항에 있어서, 키로-이소시톨에 특징적인 항체를 이용하는 상기 분석법에는 효소 관련 면역흡착 분석법, 친유성 면역 흡착 분석법 및 응집 분석법이 포함됨을 특징으로 하는 방법.
  5. 인슐린 저항성의 내력을 갖고 있는 가계로부터 환자를 선택하고, 상기 환자로부터 혈청 또는 뇨 시료를 채취하고, 상기 시료 중의 키로-이노시톨 존재를 측정하여 상기 뇨 시료 중의 키로-이노시톨 농도가 약 1.0㎍/ml 이하이면 인슐린 저항성 발병이 예견되는 개체로서 분석함을 특징으로 하는 인슐린 저항성 발병이 예견되는 환자의 선별 방법.
  6. 당뇨병 환자의 키로-이노시톨 농도를 장기간 모니터하여 뇨 중에 약 1.0㎍/ml 미만 및 혈청 중에 약 0.1㎍/ml 미만으로 키로-이노시톨 농도가 떨어지면 적합한 치료 변경을 필요로 하는 잠재적 인슐린 저항성을 나타내는 것으로 분석함을 특징으로 하는, 당뇨병 환자에게 투여되는 인슐린 요법의 효과를 모니터하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910701268A 1990-02-08 1991-02-06 당뇨병 예보자의 정량 분석 KR0175314B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47695390A 1990-02-08 1990-02-08
US476,953 1990-02-08
US476953 1990-02-08
PCT/US1991/000655 WO1991012335A1 (en) 1990-02-08 1991-02-06 Quantitative analysis of chiroinositol as a diabetic condition predictor

Publications (2)

Publication Number Publication Date
KR920701472A true KR920701472A (ko) 1992-08-11
KR0175314B1 KR0175314B1 (ko) 1999-02-01

Family

ID=23893914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701268A KR0175314B1 (ko) 1990-02-08 1991-02-06 당뇨병 예보자의 정량 분석

Country Status (12)

Country Link
EP (1) EP0468031B1 (ko)
JP (1) JP3118458B2 (ko)
KR (1) KR0175314B1 (ko)
AT (1) ATE151464T1 (ko)
AU (2) AU651572B2 (ko)
CA (1) CA2051630A1 (ko)
DE (1) DE69125536T2 (ko)
DK (1) DK0468031T3 (ko)
ES (1) ES2101742T3 (ko)
GR (1) GR3023760T3 (ko)
NO (1) NO303598B1 (ko)
WO (1) WO1991012335A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525526A (en) * 1994-02-02 1996-06-11 The University Of Virginia Patent Foundation Immunoassay for inositols
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
WO1998042863A1 (fr) * 1997-03-26 1998-10-01 Asahi Kasei Kogyo Kabushiki Kaisha Procede hautement sensible de dosage du chiro-inositol et compositions destinees au dosage
CA2374269C (en) 1999-05-20 2007-04-24 Humanetics Corporation Stimulating transport of glucose into animal tissue by the administration of pinitol
JP4602577B2 (ja) 2001-03-15 2010-12-22 積水メディカル株式会社 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69024348T2 (de) * 1989-03-08 1996-08-14 Univ Virginia Verfahren zum nachweis des diabetischen zustandes

Also Published As

Publication number Publication date
GR3023760T3 (en) 1997-09-30
CA2051630A1 (en) 1991-08-09
ATE151464T1 (de) 1997-04-15
EP0468031B1 (en) 1997-04-09
DE69125536T2 (de) 1997-07-17
AU662268B2 (en) 1995-08-24
AU7141094A (en) 1994-11-24
KR0175314B1 (ko) 1999-02-01
WO1991012335A1 (en) 1991-08-22
JP3118458B2 (ja) 2000-12-18
AU7253191A (en) 1991-09-03
DK0468031T3 (da) 1997-05-12
ES2101742T3 (es) 1997-07-16
NO913884L (no) 1991-10-03
NO303598B1 (no) 1998-08-03
EP0468031A1 (en) 1992-01-29
EP0468031A4 (en) 1991-11-27
DE69125536D1 (de) 1997-05-15
NO913884D0 (no) 1991-10-03
AU651572B2 (en) 1994-07-28
JPH04505218A (ja) 1992-09-10

Similar Documents

Publication Publication Date Title
Jinchuan et al. Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus
Golka et al. Carbohydrate-deficient transferrin (CDT)—a biomarker for long-term alcohol consumption
Yue et al. Free thyroid hormones in serum by direct equilibrium dialysis and online solid-phase extraction–liquid chromatography/tandem mass spectrometry
Bürgi et al. One-step sandwich enzyme immunoassay for insulin using monoclonal antibodies
Kroll et al. Interference with clinical laboratory analyses
Koshimura et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy
Osicka et al. Characterization of immunochemically nonreactive urinary albumin
Tames et al. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects
Dods et al. Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus.
JP4619372B2 (ja) 改良された対照区画を有する免疫学的試験素子
JONES et al. 5.2 MEASURING BLOOD-ALCOHOL CONCENTRATION FOR CLINICAL AND FORENSIC PURPOSES
Zanella et al. Sensitivity and predictive value of serum ferritin and free eiythrocyte protoporphyrin for iron deficiency
KR100394940B1 (ko) 간 질환 진단을 위한 혈중 아사이알로당단백질양의측정방법 및 측정용 킷트
Collinson et al. Cardiac troponin T in renal disease
Thevarajah et al. Interference of hemoglobinA1c (HbA1c) detection using ion-exchange high performance liquid chromatography (HPLC) method by clinically silent hemoglobin variant in University Malaya Medical Centre (UMMC)—A case report
Mashiba et al. Measurement of glycated albumin by the nitroblue tetrazolium colorimetric method
KR920701472A (ko) 당뇨병 예보자의 정량 분석
Tsilingiris et al. Effect of heterozygous beta thalassemia on HbA1c levels in individuals without diabetes mellitus: a cross sectional study
Koga et al. Serum 1, 5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes
Chrostek et al. The diagnostic accuracy of carbohydrate-deficient transferrin, sialic acid and commonly used markers of alcohol abuse during abstinence
Boonprasert et al. Validation of an electrochemical sensor based on gold nanoparticles as a point-of-care test for quantitative determination of glycated hemoglobin
Moyer et al. Filter paper lead testing
English et al. In vitro determination of hemoglobin A1c for diabetes diagnosis and management: technology update
Laing et al. Serum sex‐hormone‐binding globulin is related to hepatic and peripheral insulin sensitivity but not to beta‐cell function in men and women with Type 2 diabetes mellitus
Yuan et al. The association between self-monitoring of blood glucose and HbA1c in type 2 diabetes

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee